20h
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss
FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...
A federal appeals court is deciding whether to revive more than 500 lawsuits claiming cases of autism or ADHD was caused by ...
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of ...
Our data at ASH 2025 raises the bar for patient and physician expectations of what’s possible. Our long-term data drives confidence in duration of response in CLL treatment decisions,” said Lai Wang, ...
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback